Perspective Therapeutics (CATX) AI Stock Analysis

• Market Cap: $246.44M
• Dividend Yield: N/A
• Average Volume (3M): 1.05M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 138
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): -0.25
• Shares Outstanding: 74,228,330
• 10 Day Avg. Volume: 1,776,895
• 30 Day Avg. Volume: 1,047,204
• PEG Ratio: 0.26
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.30
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: 28.79
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.88
• 1Y Price Target: $13.00
• Price Target Upside: 302.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 41 Neutral
• Price Target: ―

Perspective Therapeutics is facing severe operational challenges with no revenue and increasing net losses, which significantly impact its financial performance score. While the company's balance sheet shows some strength due to low leverage, the reliance on external financing raises sustainability concerns. The technical analysis indicates ongoing downward pressure, and the negative P/E ratio reflects severe valuation concerns. Overall, the stock's prospects are weak, requiring strategic turnaround efforts to improve its outlook.

Positive Factors

Clinical Efficacy

The presentation of preliminary data from the Pb-212-VMT-α-NET trial could indicate strong clinical activity comparable to impressive response rates seen in other trials.

Financial Stability

CATX reported a preliminary estimated unaudited cash position of approximately $227.8M, which is expected to fund operations into late 2026, indicating strong financial stability.

Safety Profile

The safety profile of VMT-α-NET continues to look promising with no dose-limiting toxicities, no Grade 4 or 5 treatment emergent adverse events, no discontinuations due to adverse events, no serious adverse events related to treatment, and only 24% of patients experienced a Grade 3 treatment emergent adverse event.

Negative Factors

Efficacy Concerns

Concerns over potential reduced efficacy compared to a competitor may be assuaged as the improvement in patient response is noted.

Perspective Therapeutics Business Overview & Revenue Model

Company Description

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

How the Company Makes Money

Perspective Therapeutics makes money primarily through the commercialization of its proprietary therapeutic solutions. The company generates revenue by licensing its technologies to pharmaceutical companies, receiving milestone payments and royalties from successful product developments. Additionally, Perspective Therapeutics may engage in strategic partnerships and collaborations with other biotech firms and research institutions to co-develop products, further expanding its revenue streams. The company may also earn income from government grants and subsidies aimed at fostering innovation in healthcare.

Perspective Therapeutics Financial Statement Overview

Summary

Perspective Therapeutics faces critical challenges with no revenue generation and increasing net losses. The company's strong equity base and low leverage offer some financial stability, but the dependency on external financing and poor cash flow metrics raise concerns about its sustainability. Immediate strategic adjustments are essential to improve revenue generation and operational efficiency.

Income Statement

Perspective Therapeutics shows significant challenges in its income statement. Revenue has declined to zero in the most recent year from $1.43 million the previous year, indicating severe operational challenges. The net loss has widened significantly, exacerbating concerns about profitability and sustainability. The EBIT margin has improved due to reduced negative EBIT, but this is overshadowed by the lack of revenue.

Balance Sheet

The balance sheet reflects a strong equity position with low debt levels, evidenced by a debt-to-equity ratio of approximately 0.01. The company maintains a high equity ratio, suggesting financial stability despite ongoing losses. However, the substantial net losses indicate that the company is heavily reliant on external financing, posing a risk to long-term viability.

Cash Flow

Cash flow analysis shows substantial negative free cash flow, reflecting significant cash burn. The large financing cash flow indicates reliance on external funding to support operations. The operating cash flow to net income ratio is negative, as is the free cash flow to net income ratio, demonstrating inefficiency in converting income into cash.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Jun 2022	Jun 2021
Income Statement		Total Revenue
0.00	1.43M	7.10M	10.79M	10.05M
	Gross Profit
0.00	1.43M	1.63M	4.62M	5.12M
	EBIT
10.46M	-40.94M	-15.18M	-7.39M	-3.44M
	EBITDA
10.46M	-39.96M	-14.84M	-7.39M	-3.43M
	Net Income Common Stockholders
-79.28M	-46.51M	-14.67M	-7.15M	-3.19M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
226.92M	9.24M	43.76M	55.89M	63.83M
	Total Assets
341.10M	97.89M	58.09M	64.44M	70.42M
	Total Debt
2.38M	2.55M	0.00	524.00K	776.00K
	Net Debt
-59.20M	-6.69M	-20.99M	-55.37M	-63.05M
	Total Liabilities
50.43M	22.71M	3.45M	3.16M	3.01M
	Stockholders Equity
290.67M	75.18M	54.64M	61.28M	67.41M
Cash Flow		Free Cash Flow
-72.71M	-37.98M	-12.47M	-7.98M	-3.22M
	Operating Cash Flow
-18.29M	-36.91M	-12.17M	-7.71M	-2.84M
	Investing Cash Flow
-218.93M	24.37M	-57.68M	-284.00K	-410.00K
	Financing Cash Flow
289.38M	785.00K	56.00K	56.00K	64.68M

Perspective Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.23
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CATX, the sentiment is Positive. The current price of 3.23 is above the 20-day moving average (MA) of 2.69, above the 50-day MA of 2.37, and below the 200-day MA of 6.10, indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 63.88 is Neutral, neither overbought nor oversold. The STOCH value of 66.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CATX.

Perspective Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BWAY	77 Outperform	$202.08M	48.25	7.41%	―	26.86%	―
MASS	58 Neutral	$248.88M	―	-44.97%	―	21.06%	-99.70%
LNSR	54 Neutral	$156.07M	―	-304.05%	―	28.24%	-334.39%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
MYO	53 Neutral	$107.22M	―	-35.68%	―	69.17%	39.01%
CVRX	52 Neutral	$171.04M	―	-76.01%	―	25.62%	11.86%
CATX	41 Neutral	$246.44M	―	-32.92%	―	―	―

Perspective Therapeutics Corporate Events

Perspective Therapeutics Appoints New Chief Financial Officer

Perspective Therapeutics has appointed Juan Graham as the new Chief Financial Officer, succeeding Jonathan Hunt who remains as Chief Accounting Officer. With nearly 25 years of experience in biopharmaceutical financial management, Graham’s expertise is expected to enhance the company’s strategic financial operations and support its growth, particularly as it advances its clinical programs and builds manufacturing infrastructure.